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Abstract: Tinnitus disability is a heterogeneous and complex condition, affecting more than 10%
and compromising the quality of life of 2% of the population, with multiple contributors, often
unknown, and enigmatic pathophysiology. The available treatment options are unsatisfactory, as they
can, at best, reduce tinnitus severity, but not eliminate its perception. Given the spread of tinnitus
and the lack of a standardized treatment, it is crucial to understand the economic burden of this
condition. We conducted a systematic review of the literature on PubMed/MEDLINE, Embase, the
Cochrane Database of Systematic Reviews (CDSR) and Google Scholar, in order to identify all the
articles published on the economic burden of tinnitus before 1 April 2021 (PROSPERO—International
prospective register of systematic reviews—No: CRD42020180438). Out of 273 articles identified
through our search strategy, only five articles from studies conducted in the United States of America
(USA), the Netherlands and the United Kingdom (UK) provided data on tinnitus’s economic costs.
Three studies provided mean annual estimates per patient ranging between EUR 1544 and EUR 3429
for healthcare costs, between EUR 69 and EUR 115 for patient and family costs and between EUR
2565 and EUR 3702 for indirect costs, including productivity loss. The other two studies reported an
annual mean cost of EUR 564 per patient for tinnitus-related clinical visits, and total costs of EUR
1388 and EUR 3725 for patients treated with a sound generator and Neuromonics Tinnitus Treatment,
respectively. Our comprehensive review shows a gap in the knowledge about the economic burden
of tinnitus on healthcare systems, patients and society. The few available studies show considerable
expenses due to healthcare and indirect costs, while out-of-pocket costs appear to be less financially
burdensome. Comprehensive health economic evaluations are needed to fill the gaps in current
knowledge, using a unified method with reliable and standardized tools.
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1. Introduction
Tinnitus is a continuous auditory perception in the ears or head in the absence of a
corresponding external stimulus [1]. Tinnitus can become a chronic health problem, and it
affects 10–15% of the general adult population, with 1–5% of adults severely impacted [1–5].
Tinnitus prevalence increases with older age, reaching up to 40% among the elderly [2,3].
The incidence of tinnitus is expected to grow as a consequence of the increase in industrial-
ization worldwide and a longer lifespan [6]. Approximately 10% of subjects with tinnitus
develop mild to severe disability. Severe disabling tinnitus, being strongly associated with
depression, anxiety, insomnia, difficulty concentrating and poor psychological well-being,
significantly negatively impacts quality of life [2–6].
When disabling and impacting daily functioning, tinnitus is a heterogeneous and
complex condition with multiple associated biological, psychological and contextual con-
tributors, which often remain unknown [7]. Moreover, with increasing severity, it appears
to segregate in families, suggesting a genetic cause as well [8,9]. The available treatment
options are unsatisfactory [10,11]. Multiple treatments have been proposed for tinnitus,
and many of them have shown efficacy in a subgroup of patients [12]. Still, it is currently
difficult to predict the optimal and most promising treatment for an individual tinnitus
patient. The few evidence-based treatment options efficacious for every tinnitus are aimed
at ameliorating the disability caused by tinnitus rather than eliminating the perception [13].
Indeed, the most widespread of these management therapies consist of auditory stimu-
lation and cognitive-behavioral therapy, aiming at modulating mechanisms that would
otherwise maintain tinnitus disability [5,6].
Consequently, people suffering from this condition try out various possible treatments,
one after the other [12], and refer to a variety of caregivers in unstructured and non-
standardized ways, in the hope of finding proper treatment [14]. This creates high costs
both for patients and healthcare systems and complicates cost evaluations, facing several
challenges when aiming to include all the treatment pathways followed by patients. Indeed,
over 4 million prescriptions are written every year in Europe and the USA for tinnitus
relief, but these are all off-label prescriptions from a wide variety of therapeutic drugs with
uncertain efficacy [5,6], even though there is a recommendation against medication for
tinnitus in the European guidelines [15].
Thus, tinnitus management carries a significant financial burden for both healthcare
systems and society, including patients [16]. Expenses related to the management of
tinnitus are not limited to direct medical costs (e.g., specialist’s visits, purchasing drugs or
other medical devices) but also include individual indirect costs such as travel expenses,
costs for recommended activities (such as sport or meditation), costs for family members
and loss of income because of reduced working capabilities. Tinnitus frequently leads
to a work-related disability, often resulting in compensation of payments. For example,
in 2012, the United States Department of Veterans Affairs (VA) spent USD 1.2 billion on
tinnitus-related compensation to veterans [16]. Moreover, in many cases, tinnitus causes
sick leave and disability pension [17,18]. Thus, the financial burden tinnitus imposes on
governments and industries is significant [6]. Moreover, tinnitus correlates with impaired
quality of life, which could be further estimated in terms of costs. Indeed, at least two
studies showed that high healthcare costs were substantial in terms of quality-adjusted life
years (QALYs) per person [19,20].
Given the spread of tinnitus and the currently still relatively low investment in tinnitus
research [21], which leads to a lack of standardized treatment for this condition, it is
crucial to understand the exact economic burden of tinnitus. This study aims to conduct a
systematic review to collect information on both direct (medical and non-medical costs)
and indirect costs (including societal costs, such as work loss and reduced productivity)
for tinnitus management from the available scientific literature. This will allow us to
describe the costs for the healthcare system and tinnitus patients under the current practice.
The results of this systematic review will help us understand and evaluate the extent of
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evidence currently available on the financial burden of tinnitus and identify potential gaps
to direct future research.
2. Materials and Methods
2.1. Data Sources and Search Strategy
The following scientific databases were considered to conduct this systematic literature
search: PubMed/MEDLINE, Embase and the Cochrane Database of Systematic Reviews
(CDSR). A search on Google Scholar was also performed in order to identify relevant
articles published in scientific journals not indexed in those databases. In addition, the
databases of the World Health Organization (WHO), Eurostat and the Organisation for
Economic Co-operation and Development (OECD) were consulted to retrieve possible
additional relevant information about direct and indirect costs associated with tinnitus
and related quality-adjusted life years. The search strategy was designed for PubMed and
then adapted for use in the other databases. Search terms included terms for the condition
and the considered outcome (i.e., “tinnitus AND (economic OR costs OR market OR “Cost
of Illness” OR QALY)). We did not apply any restriction on publication time, considering
all scientific articles published in English before the search date. Articles published in
a language other than English were excluded from the review. Reference lists of other
reviews were also checked to identify other potentially relevant publications.
On 1 April 2021, we applied the search strategy. Overall, through PubMed, 137
publications were identified, with an additional 14 on Embase, 28 on CDSR and 170 publi-
cations on Google Scholar. Excluding duplicates, we obtained a total of 273 publications
(Supplementary Figure S1).
2.2. Eligibility Criteria
In order to be eligible, studies had to provide data on direct or indirect costs due to
the management of tinnitus disability in human subjects. We excluded studies on animals
or biological tissues. We did not apply restrictions on the type of study design; thus,
studies considered for inclusion were: cross-sectional studies (including population-based
surveys on specific sub-populations), case–control studies, cohort studies, clinical trials
and case series. Both original articles and reviews were considered, while unpublished
studies, conference abstracts and proceedings, dissertations, theses and, more generally,
non-peer-reviewed papers were not considered.
2.3. Study Selection
We combined those publications detected on various databases in an EndNote library
(i.e., a software for reference management). In the first screening, two reviewers evaluated
titles and abstracts independently to identify publications that met our inclusion criteria.
The reviewers independently assigned scores 1–5 to the articles as follows: 1 = Publication
not pertinent or of limited interest for our review; 2 = Publication probably not pertinent
or of limited interest; 3 = Not possible to evaluate based on title/abstract/keywords only;
4 = Publication probably pertinent or of interest; 5 = Publication pertinent or of clear interest
for our review. After the first screening, the two reviewers’ scores were added, obtaining
total scores ranging from 2 to 10. A publication with a combined score of 4 or less was not
considered for further evaluation. In the second screening, the full text of all the potentially
eligible studies was retrieved and independently assessed for eligibility by two reviewers.
2.4. Data Extraction
For each publication satisfying the eligibility criteria, we collected: (a) general informa-
tion on the publication (first author, year of publication, journal), (b) study characteristics
(country, calendar period, study design, sample size), (c) data on direct and indirect costs
for tinnitus management, and (d) the model used to compute the estimates (including
adjustments). In order to allow for comparisons, all costs were converted from the local
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currency into EUR (conversion rate: USD 1 = EUR 0.85; GBP 1 = EUR 1.10). Data extraction
was performed using Microsoft Excel and EndNote X7.
3. Results
Out of 273 identified publications, 26 were included after the first screening of titles
and abstracts. Of these, only five articles met the eligibility criteria and were included in the
present systematic review. No relevant additional information was found in the databases
of the WHO, Eurostat and OECD. Table 1 shows the description of eligible included studies.
Two studies were conducted in the USA: a cross-sectional study from 2011, analyzing a
sample of 692 tinnitus patients, estimated that the annual average tinnitus-related costs per
patient for clinical visits were EUR 564 (standard deviation, SD: EUR 1186) [22]; a cohort
study evaluated the treatment costs during a 1-year period of follow-up of 56 tinnitus
patients, treated either with sound generators or the Neuromonics Tinnitus Treatment.
Treatment costs were EUR 1388 for sound generators and EUR 3725 for the Neuromonics
Tinnitus Treatment [23].
A cross-sectional study from the Netherlands provided direct and indirect annual
mean costs per patient. Total annual mean healthcare costs added up to EUR 1544, patient
and family costs to EUR 69 and costs due to productivity loss to EUR 3702 [7]. This study
reported higher costs for patients with severe compared to moderate and mild tinnitus. In
particular, healthcare costs were EUR 767, EUR 1329 and EUR 2218 for patients with mild,
moderate and severe tinnitus, respectively. The corresponding estimates for patients and
family costs were EUR 31, EUR 61 and EUR 115, and those due to productivity loss were
EUR 1222, EUR 4781 and EUR 5105.
A randomized controlled trial (RCT) from the Netherlands conducted in 2007–2011 on
492 tinnitus patients estimated annual mean direct and indirect costs per patient divided
by usual care (UC) and specialized care (SC). The study provided healthcare costs (UC:
EUR 3300; SC: EUR 3429), patient and family costs (UC: EUR 115; SC: EUR 90) and costs
due to a loss of productivity (UC: EUR 2565; SC: EUR 2764). Thus, estimates for the total
annual costs (i.e., the sum of the three categories mentioned above) were EUR 5980 for UC
and EUR 6283 for SC [19].
The last eligible included study was a cohort study conducted in the UK, estimat-
ing mean annual direct costs expressed as healthcare costs only. The mean annual total
healthcare costs were EUR 1938 [20]. Indirect costs and patient and family costs were not
provided in this publication.
The costs identified in studies that provided healthcare, patient and family and indirect
costs are graphically presented in Figure 1.
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Figure 1 Annual healthcare, patient and family and indirect costs (where available *) for tinnitus management in 3 studies 
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[23] are not presented in this figure since they did not provide an estimate of overall societal or healthcare costs but only 
provided estimates for clinical visits, and for sound generators and Neuromonics Tinnitus Treatment. 
 
Figure 1. Annual healthcare, patient and family and indirect costs (where available *) for tinnitus management in 3 studies
◦. * The study by Stockdale et al., 2017 [20] provided information on healthcare costs only. Indirect costs and patient and
family costs were not provided in this publication. ◦ Studies by Goldstein et al., 2015 [22] and Newman and Sandrige,
2012 [23] are not presented in this figure since they did not provide an estimate of overall societal or healthcare costs but
only provided estimates for clinical visits, and for sound generators and Neuromonics Tinnitus Treatment.
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Table 1. Description of eligible studies included in this systematic review.
First Author,
Year [reference] Study Design
Country (Study
Period) Tinnitus Cost Determination Study Population Outcome Measures Estimates
Goldstein, 2015
[22] Cross-sectional USA (2011)
Costs were estimated through
local hospital data stores
Sample of 692 patients
with subjective tinnitus
who visited the clinic in
2011
Total annual clinical costs
for tinnitus-related visits
Estimates are provided in annual mean per person (SD)






Cost estimates were based on
patient charges for each
treatment option
56 patients enrolled from a
tinnitus clinic: 23 treated
with SG, 33 with NTT
Healthcare costs for 1 year
of two specific treatments
SGs total costs: USD 1633 (i.e., EUR 1388)
NTT total costs: USD 4382 (i.e., EUR 3725)
Maes, 2013 [7] Cross-sectional Netherlands (notspecified)
Costs were estimated using a
self-administered questionnaire
with a recall period of 3 months.
The mean costs were then
multiplied by 4 to obtain
annual mean costs per patient.




Mean annual costs divided
into three categories:
healthcare costs, patient
and family costs and
indirect costs
Healthcare costs: EUR 1544
These costs include those for GP practice (EUR 225; visit, home visit, assistant visit,
weekend and evening), medical specialists (EUR 771; ENT specialist visit, dental
surgeon visit, neurologist visit, other medical specialists), other healthcare
professionals (EUR 527; clinical physicist in audiology, physiotherapist, psychologist,
psychiatrist, social worker, occupational therapist, company doctor, homeopath,
acupuncturist, haptonomist, magnetizer), prescribed medication (EUR 21).
Patient and family costs: EUR 69
These costs include over-the-counter medication, traveling expenses, sports,
medication, ear candle, other costs.
Productivity loss (loss of productivity at paid labor): EUR 3702
Total annual costs: EUR 5315
Maes, 2014 [19] RCT Netherlands(2007–2011)
Costs were estimated from the
exact amount of care consumed
at the audiologic center by each
patient, from the GIP databank
2009 and from the information
of the Dutch Association of
Hearing Aid Dispensers.
492 tinnitus patients who
referred to the audiologic
center and were
randomized to SC or UC
Mean annual costs divided
into three categories:
healthcare costs, patient
and family costs and
indirect costs
Healthcare costs: UC: USD 3882 (i.e., EUR 3300) and SC: USD 4034 (i.e., EUR 3429)
These costs include first-level tinnitus care (UC: USD 1848 and SC: USD 2091; pure
tone audiometry, speech audiometry, tympanometry, tinnitus analysis, uncomfortable
loudness levels, individual consult by clinical physicist in audiology, hearing aid
fitting, new hearing aid, hearing aid check and optimization, fitting tinnitus masker,
new tinnitus masker, BERA, intake psychologist, tinnitus educational group session),
second-level tinnitus care (UC: USD 365 and SC: USD 694; individual trajectory,
treatment group A, treatment group B, social work trajectory), general practitioner
practice (UC: USD 166 and SC: USD 97; GP visit, GP home visit, GP assistant visit, GP
weekend and evening), hospital care (UC: USD 562 and SC: USD 479; ENT specialist
visit, neurologist visit, dental surgeon visit, other medical specialist), other healthcare
professionals (UC: USD 941 and SC: USD 674; physiotherapist, psychologist,
psychiatrist, social worker, occupational therapist, company physician, homeopath,
acupuncturist, haptonomist, magnetizer), prescribed medication.
Patient and family costs: UC: USD 135 (i.e., EUR 115), SC: USD 106 (i.e., EUR 90)
These are divided into: over-the-counter medication, traveling expenses, sports,
medication or other costs.
Productivity loss (loss of productivity at paid labor): UC: USD 3018 (i.e., EUR 2565),
SC: USD 3252 (i.e., EUR 2764)
Total annual costs: UC: USD 7035 (i.e., EUR 5980) SC: USD 7392 (i.e., EUR 6283)
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Table 1. Cont.
First Author,
Year [reference] Study Design
Country (Study





A cost model was constructed
considering the most common
treatment pathways and was
applied to a cohort of patients
Cohort of patients
referring to a GP for
tinnitus for the first time
Annual healthcare
treatment costs
Digital hearing aids: GBP 85
Hearing aids assessments: GBP 65
Hearing aid fitting: GBP 65
Hearing aid follow-up: GBP 108
Hearing aid batteries: GBP 12
Hearing aid repairs: GBP 52
CBT: GBP 471
Tinnitus therapy plus wearable sound generator: GBP 303




Associate medical specialist in ENT: GBP 121
Audiologist (1 h): GBP 19
Clinical psychologist (2 h): GBP 286
Total healthcare costs: GBP 1762 (i.e., EUR 1938)
BERA: brainstem evoked response audiometry; CBT: cognitive-based therapy; ENT: ear, nose and throat; GP: general practitioner; MRI: magnetic resonance imaging; NTT: Neuromonics Tinnitus Treatment; RCT:
randomized controlled trial; SC: standard care; SD: standard deviation; SG: sound generator; UC: usual care.
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4. Discussion
4.1. Main Findings
This is the first systematic review summarizing direct and indirect costs for tinnitus
management in the current practice, based on the published scientific literature. Although
there is a wide consensus among scientific and clinical professionals that tinnitus is associ-
ated with high direct and indirect healthcare costs, our systematic review identified only
five studies that calculated costs for tinnitus management [7,19,20,22,23], with only three of
them reporting overall estimates of societal or healthcare costs [7,19,20]. Among the latter
three studies, the mean annual estimates per patient ranged between EUR 1544 and EUR
3429 for healthcare costs, between EUR 69 and EUR 115 for patient and family costs (i.e.,
out-of-pocket costs) and between EUR 2565 and EUR 3702 for indirect costs (i.e., costs due
to the loss of productivity). The other two studies reported an annual mean cost of EUR
564 per patient for tinnitus-related clinical visits [22], and total costs of EUR 1388 and EUR
3725 for patients treated with sound generators and the Neuromonics Tinnitus Treatment,
respectively [23]. These costs have been considered comparable to those observed for
unexplained pain [20].
4.2. Cost Categories
One aspect that emerged from most studies in the scientific literature and other rele-
vant databases was the lack of comprehensive and detailed information on tinnitus costs,
except for two studies from the Netherlands. Cost categories ideally include both direct
costs (direct medical and non-medical costs) and indirect costs, including societal costs (e.g.,
work loss, worker replacement, reduced productivity from illness and disease, family costs
and financial estimation of the impact on quality of life) [20,24]. This systematic review
identified only two studies, both from the Netherlands, providing a detailed description of
direct costs (healthcare, patient and family costs) and indirect costs (due to productivity
losses) [7,19]. Two additional studies provided only a portion of the overall picture of costs,
showing total healthcare costs [20] and costs for clinical visits [22].
4.3. Country Differences
In our systematic review, two of the studies reporting information on the economic
burden of tinnitus were conducted in the US [22,23], two in the Netherlands [7,19] and
one in the UK [20]. Therefore, it is evident that data on healthcare and societal costs of
tinnitus come from a very limited portion of countries worldwide. The current scientific
literature does not permit comparison among countries, since complete information on
total annual average costs for tinnitus patients comes from the Netherlands only [7,19]. To
our knowledge, no cross-border study comparing cost data in different countries, applying
the same methodology for calculating tinnitus costs, is available. This type of study
would allow investigating the impact of different healthcare systems, therapy procedures,
treatment availability and countries’ economic indicators on tinnitus-related costs.
However, an attempt for a broad estimation of the total costs in the EU could pursue
the following path: The first step would be to broadly translate expenses to the average
income of these countries and then consider the average EU income. The second step
would be to extend these estimates to the whole EU, taking into account that various
epidemiological studies estimated a prevalence of tinnitus exceeding 10%, which means
that at least 30 million people in the EU live with tinnitus.
Additionally, comparisons between countries on the costs of various treatments for
tinnitus management are lacking in the current literature. For future health economic
evaluations of treatments for disabling tinnitus, consensus on a set of standardized and
homogenous evaluative tools is of high importance, in order to facilitate cross-country and
cross-study comparisons.
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4.4. Impact of Patients’ and Tinnitus Characteristics (e.g., Severity) on Costs
Only one study conducted in the Netherlands investigated the impact of tinnitus
severity on costs, showing that the more disabled patients had significantly higher health-
care costs compared to patients with mild to moderate complaints [7]. In fact, patients with
severe tinnitus disability had more contacts with the GP, medical specialists—including
ENT specialists and neurologists—and other healthcare professionals such as psycholo-
gists, social workers and clinical physicists in audiology [7]. This study also found that
productivity losses were higher for moderate and severe tinnitus patients, compared to the
mild group. At the same time, no differences regarding out-of-pocket costs were observed
across the three groups [7]. The same study identified other relevant predictors for both
higher healthcare and societal costs, besides tinnitus severity. These included younger age,
shorter duration of tinnitus (less than 1 year) and higher scores of depression, while sex,
level of education, health-related quality of life and anxiety did not impact costs [7]. No in-
formation on the effect of other possibly relevant socio-demographic, economic and clinical
characteristics is available in the current scientific literature. Including these predictors in
other populations [20] might provide insight into the effect of socio-demographic and eco-
nomic parameters, such as family and personal socio-economic status, and tinnitus-related
characteristics on costs.
4.5. Strengths and Limitations of the Review
To our knowledge, this is the first systematic review providing a synthesis of the
healthcare and societal costs of tinnitus at an individual level in the scientific literature.
Strengths of this review include the comprehensive search strategy conducted on a large set
of scientific databases, including PubMed/MEDLINE, Embase and the CDSR. Moreover,
an additional search on Google Scholar and databases of the WHO, Eurostat and OECD
was conducted in order to check for relevant articles published in scientific journals not
indexed in the previously mentioned databases. The detailed procedure used for select-
ing articles and data extraction further assures the qualitative value of this systematic
review. Limitations include the relatively small number of included studies, leading to low
generalizability of results across countries and across patient groups.
4.6. Future Perspectives and UNITI Project
This systematic review found only a few studies dealing with the economic burden of
tinnitus, none of which were published in recent years (2018–2021). Thus, it is important
to be able to make some updated and validated statements about the economic impact of
tinnitus on the individual and society. Future studies are needed to provide new detailed
data on the healthcare and societal costs for tinnitus. Such studies are useful today because
of their implications for health policy (e.g., determining priorities by reporting tinnitus
cases that require special help, evaluating the efficacy of treatments, allocating appropriate
funds for research and development of tinnitus treatments). The framework for calculating
tinnitus costs must include data from various countries (see Section 4.3) and must consider
individual-level characteristics of tinnitus patients (e.g., sex, age, income, concomitant
comorbidities) and of the symptom itself (e.g., tinnitus onset, duration, severity) that could
determine higher costs for tinnitus management (see Section 4.4). At the same time, infor-
mation on costs per quality-adjusted life years (QALY) is scant in the literature. The UNITI
project provides the opportunity to add to the gaps in knowledge on the economic burden
of tinnitus (https://uniti.tinnitusresearch.net accessed on 1 April 2021). Within UNITI, a
large multicenter randomized controlled trial will be carried out in five clinical centers
across Europe. The cost analysis methodology of the studies from the Netherlands [7,19]
will be adopted and applied, and patient- and tinnitus-specific characteristics relevant to
tinnitus costs will be collected on all patients entering the RCT. The UNITI consortium
has committed to performing a comprehensive health economic evaluation, including an
analysis of cross-country differences.
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5. Conclusions
The current status of the scientific literature highlights a serious lack of studies esti-
mating, in detail, the economic burden of tinnitus on healthcare systems, patients, their
families and society. Available studies show considerable expenses due to healthcare costs
and indirect costs—mainly costs for productivity loss—while out-of-pocket costs appear
to be less financially burdensome. Findings also indicate a direct relationship between
tinnitus severity and related costs. Insights from existing studies point to several under-
investigated but tinnitus-relevant predictors, such as country of origin, socio-economic
factors and individual patients’ sex, age, educational level and tinnitus severity and du-
ration. Identifying the economic burden of tinnitus in various cost categories is crucial
to better understand tinnitus healthcare organization and treatment implementation in
current practice in various countries and consequently reduce unnecessary costly and
ineffective treatment strategies for patients and healthcare systems.
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.3390/ijerph18136881/s1, Figure S1: Flowchart of the systematic review.
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